Abstracts tagged "Biomarkers"

Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting
Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Nicolas Wisniacki¹, Chris Stebbins², Jadwiga Bienkowska³, Susan Gawlak², Donald Bennett⁴, Yuhong Xiang⁵, Andrea Dearth⁶, Linda C. Burkly⁷, Ann Ranger⁶, Carrie Wager⁵, Laurence S. Magder⁸ and Michelle Petri⁹, ¹Medical Research, Biogen Idec, Maidenhead, United Kingdom, ²Translational Medicine, Biogen Idec, Cambridge, MA, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biostatistics, Biogen idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec Inc, Cambridge, MA, ⁷Biogen Idec, Cambridge, MA, ⁸Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…
Abstract Number: L13 • 2013 ACR/ARHP Annual Meeting
Serum 14-3-3η Marks RA Development in Arthralgia and Radiographic Progression in Early RA Patients
D. van Schaardenburg¹, Marian van Beers-Tas², Karin Britsemmer², Mairead Murphy³, Walter P. Maksymowych⁴, Maarten Boers⁵ and Anthony Marotta⁶, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁶Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The focus of RA management is increasingly towards early detection and treatment. While newly-diagnosed patients will benefit from treatment decisions based on more robust…
Abstract Number: 2805 • 2013 ACR/ARHP Annual Meeting
Synovial Explant Inflammatory Mediator Production Is Associated With Synovitis While Not With Bone Marrow Edema In Rheumatoid Arthritis: A Cross Sectional Study
Martin Andersen¹, Mikael Boesen², Karen Ellegaard¹, Robin Christensen³, Kalle Söderström⁴, Søren Torp-Pedersen¹, Bente Danneskiold-Samsøe¹, Else Marie Bartels⁵, Nina Vendel⁶, Niels H. Søe⁷, Pieter Spee⁸, Ulrik GW Mørch⁹, Lars Karlsson⁴ and Henning Bliddal¹⁰, ¹Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ²Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Department of Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiskberg, Denmark, ³Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ⁴Biopharmaceutical Research Unit, Novo Nordisk, Translational Immunology, Biopharmaceutical Research Unit, Måløv, Novo Nordisk, Denmark, Måløv, Denmark, ⁵Rheumatology, Copenhagen University Hospital,Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ⁶Department of Anaesthesiology, Intensive Care and Operations, Gentofte University Hospital, Denmark, Hellerup, Denmark, ⁷Department of Orthopedics, Section of Hand Surgery, Gentofte University Hospital, Department of Orthopedics, Section of Hand Surgery, Gentofte University Hospital, Denmark, Hellerup, Denmark, ⁸Biopharmaceutical Research Unit Novo Nordisk, Translational Immunology, Biopharmaceutical Research Unit, Måløv, Novo Nordisk, Denmark, Måløv, Denmark, ⁹Biomarkers, Søborg, Novo Nordisk, Denmark, Biomarkers, Søborg, Novo Nordisk, Denmark, Søborg, Denmark, ¹⁰The Parker Institute, Copenhagen, Denmark
Background/Purpose: Synovitis and bone damage may represent two distinct but overlapping pathological processes in rheumatoid arthritis (RA). Whereas the bulk of synovial cells contribute to…
Abstract Number: 2082 • 2013 ACR/ARHP Annual Meeting
Interferon-Regulated Chemokine and Innate Cytokine Scores Identify Refractory Myositis Patients That Respond Better To Rtuximab Therapy
Consuelo Lopez de Padilla¹, Cynthia S. Crowson², Molly S. Hein³, Helen Khun², Rohit Aggarwal⁴, Marc C. Levesque⁵, Dana P. Ascherman⁶, Chester V. Oddis⁷ and Ann M. Reed³, ¹Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Serum cytokines play an important role in the pathogenesis of myositis by initiating and perpetuating various cellular and humoral autoimmune processes. The aim of…
Abstract Number: 1572 • 2013 ACR/ARHP Annual Meeting
High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease
Kyriakos A. Kirou¹, Mikhail Olferiev¹, Elzbieta E. Jacek¹, Mari Lliguicota¹, Margaret Robotham¹, Wei-Ti Huang², Elena Gkrouzman¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) is elevated in many patients with SLE and is associated with more severe disease. However, the relationship between elevated levels…
Abstract Number: 813 • 2013 ACR/ARHP Annual Meeting
Citrulline Specific CD4+ T Cells Exhibit a Th1 Memory Phenotype In Rheumatoid Arthritis Subjects and Their Ex Vivo Frequency Is Influenced By Both Disease Duration and Biologic Therapy
Eddie James¹, Mary Rieck², Jennifer Pieper³, John Gebe⁴, Betty Yue⁴, Megan Tatum⁵, Charlotta Sandin⁶, Lars Klareskog⁷, Vivianne Malmström⁸ and Jane Buckner⁹, ¹Benaroya Research Institute, Seattle, WA, ²Translational Research Program, Benaroya Research Institute, Seattle, WA, ³Department of Medicine, Karolinska Institutet, Rheumatology Unit, Stockholm, Sweden, ⁴Diabetes Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁹Translational Research Program, Benaroya Research Institute, Seattle, WA 98101, USA,, Seattle, WA
Background/Purpose: Rheumatoid arthritis is thought to be a T cell mediated disease, based on its strong association with HLA class II alleles, clinical responsiveness to…
Abstract Number: 2756 • 2013 ACR/ARHP Annual Meeting
Serum Periostin Is Associated With Prevalent Knee Osteoarthritis and Predicts Disease Progression In Women: The Ofely Study
Jean-Charles Rousseau¹, Elisabeth Sornay-Rendu¹, Cindy Bertholon¹, Patrick Garnero² and Roland Chapurlat³, ¹INSERM UMR 1033, Lyon, France, ²INSERM, UMR 1033, Lyon and Cisbio Bioassays, Bagnols/Cèze, France, ³Service de Rhumatologie et Pathologie Osseuse, INSERM UMR 1033 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France
Background/Purpose: Periostin (POSTN) is a secreted vitamin K-dependent (Gla-containing) protein produced by osteoblasts and chondrocytes. The aim of this study was to investigate the relationships…
Abstract Number: 2057 • 2013 ACR/ARHP Annual Meeting
Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – The RIM (Rituximab in Myositis) Trial
Ann M. Reed¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla³, Helen Khun², Rohit Aggarwal⁴, Dana P. Ascherman⁵, Marc C. Levesque⁶ and Chester V. Oddis⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The aim of this study was to examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies (autoAbs) as biomarkers of…
Abstract Number: 1453 • 2013 ACR/ARHP Annual Meeting
Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA^® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Shintaro Hirata¹, Wanying Li², Nadine A. Defranoux², Rebecca Bolce², Eric H. Sasso², Satoshi Kubo¹, Shunsuke Fukuyo¹, Kentaro Hanami³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score that is based on the serum concentrations of 12 biomarkers has been shown to correlate with clinical…
Abstract Number: 651 • 2013 ACR/ARHP Annual Meeting
Growth Differentation Factor-15, a Marker Of lung disease In Systemic Sclerosis, Is Involved In Fibrosis Development But Does Not Impair Fibrosis Development
Stijn Lambrecht¹, Vanessa Smith², Katelijne De wilde³, Julie Coudenys⁴, Filip De Keyser² and Dirk Elewaut⁵, ¹Dept of Rheumatology, Laboratory for Molecular Immunology and Inflammation, Ghent University, Ghent, Belgium, ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Deptartment of Rheumatology, Ghent University, Ghent, Belgium, ⁴Dept of Rheumatology, Ghent University, Ghent, Belgium, ⁵Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium
Background/Purpose: It is generally known that members of the TGF-β superfamily are involved in the regulation of connective tissue biology in systemic sclerosis (SSc). Growth…
Abstract Number: 2251 • 2012 ACR/ARHP Annual Meeting
High Sensitivity C-Reactive Protein, Disease Activity and Cardiovascular Risk Factors in Systemic Lupus Erythematosus
Chi Chiu Mok¹, Daniel Birmingham², Ling Yin Ho¹ and Brad H. Rovin³, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Medicine, Ohio State University Medical Center, Columbus, OH, ³Division of Nephrology, Ohio State University Medical Center, Columbus, OH

Background/Purpose: To study the level of high-sensitivity C-reactive protein (hsCRP) and its relationship with disease activity, damage and cardiovascular risk factors in patients with systemic…
Abstract Number: 1471 • 2012 ACR/ARHP Annual Meeting
Differential Expression of Hepatocyte Growth Factor (HGF) in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Lorinda Chung¹, Catriona Cramb², William H. Robinson³, Virginia D. Steen⁴ and Roham T. Zamanian⁵, ¹Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ²VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ³Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ⁵Stanford University, Palo Alto, CA
Background/Purpose: Pulmonary arterial hypertension (PAH) is one of the leading causes of death in patients with systemic sclerosis (SSc). Non-invasive biomarkers are needed to identify…
Abstract Number: 839 • 2012 ACR/ARHP Annual Meeting
Urinary Levels of High Mobility Group Box 1 Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology
Irene Blanco¹, Neelakshi Jog², Chaim Putterman³, Iris Lee⁴ and Roberto Caricchio⁵, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Temple University, Philadelphia, PA, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Nephrology, Temple University, Philadelphia, PA, ⁵Medicine/Rheumatology, Temple University, Philadelphia, PA
Background/Purpose: High mobility group box 1 protein (HMGB-1) had been implicated in the pathogenesis of SLE and potentially lupus nephritis (LN). There is increased expression…
Abstract Number: 560 • 2012 ACR/ARHP Annual Meeting
Proteomic Profiling of Synovial Fluid Reveals Candidate Psoriatic Arthritis Biomarkers
Daniela Cretu¹, Ihor Batruch², Punit Saraon³, Dafna D. Gladman⁴, Fawnda Pellett⁵, Eleftherios Diamandis⁶ and Vinod Chandran⁷, ¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, ON, Canada, ²Department of Pathology and Lab Medicine,, Mount Sinai Hospital, Toronto, ON, Canada, ³Department of Pathology and Lab Medicine, Mount Sinai Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ⁷Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a unique form of arthritis occurring in 30% of psoriasis patients. There is a high prevalence of undiagnosed PsA in…
Abstract Number: 2261 • 2012 ACR/ARHP Annual Meeting
Ovarian Reserve Markers in Reproductive Age Women with Systemic Lupus Erythematosus
Olívio B. Malheiro¹, Carolina P. Rezende¹, Gilda A. Ferreira² and Fernando M. Reis¹, ¹Obstetrics and Gynecology, Federal University of Minas Gerais, Belo Horizonte, Brazil, ²Locomotor System Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem disease, which affects mostly women at reproductive age, and can promote premature ovarian dysfunction related to factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].